Khrom Capital Management LLC Takes $25 Million Position in HCA Healthcare, Inc. (NYSE:HCA)

Khrom Capital Management LLC purchased a new position in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 83,294 shares of the company's stock, valued at approximately $25,001,000. HCA Healthcare comprises 2.8% of Khrom Capital Management LLC's holdings, making the stock its 13th biggest holding.

A number of other hedge funds also recently modified their holdings of HCA. Eversept Partners LP lifted its stake in HCA Healthcare by 36.2% during the fourth quarter. Eversept Partners LP now owns 175,808 shares of the company's stock worth $52,769,000 after purchasing an additional 46,724 shares during the last quarter. Hsbc Holdings PLC lifted its position in shares of HCA Healthcare by 13.1% in the 4th quarter. Hsbc Holdings PLC now owns 384,529 shares of the company's stock worth $115,299,000 after purchasing an additional 44,499 shares during the period. Tower Research Capital LLC TRC grew its holdings in HCA Healthcare by 96.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,135 shares of the company's stock worth $3,342,000 after acquiring an additional 5,469 shares during the period. Mirabella Financial Services LLP bought a new position in shares of HCA Healthcare during the 4th quarter worth approximately $10,569,000. Finally, Natixis boosted its position in shares of HCA Healthcare by 51.4% during the 4th quarter. Natixis now owns 128,586 shares of the company's stock worth $38,595,000 after purchasing an additional 43,628 shares in the last quarter. Institutional investors and hedge funds own 62.73% of the company's stock.

Insider Activity

In other news, SVP Jennifer Berres sold 9,533 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $322.59, for a total transaction of $3,075,250.47. Following the transaction, the senior vice president now directly owns 15,412 shares in the company, valued at $4,971,757.08. The trade was a 38.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 1.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Guggenheim initiated coverage on shares of HCA Healthcare in a research note on Wednesday, April 9th. They issued a "neutral" rating on the stock. Bank of America dropped their price objective on HCA Healthcare from $380.00 to $370.00 and set a "buy" rating on the stock in a research note on Monday, January 27th. StockNews.com lowered shares of HCA Healthcare from a "buy" rating to a "hold" rating in a research report on Wednesday, April 9th. Royal Bank of Canada decreased their price target on shares of HCA Healthcare from $405.00 to $384.00 and set an "outperform" rating on the stock in a research note on Monday, January 27th. Finally, Barclays cut their price target on shares of HCA Healthcare from $392.00 to $366.00 and set an "overweight" rating for the company in a research report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $381.67.

HCA Healthcare Price Performance

HCA stock traded down $2.11 during trading on Friday, hitting $339.31. The stock had a trading volume of 262,741 shares, compared to its average volume of 1,389,201. The stock has a market capitalization of $83.54 billion, a P/E ratio of 15.45, a PEG ratio of 1.10 and a beta of 1.48. The company has a debt-to-equity ratio of 69.07, a current ratio of 1.08 and a quick ratio of 0.97. HCA Healthcare, Inc. has a twelve month low of $289.98 and a twelve month high of $417.14. The company's 50-day moving average price is $329.61 and its two-hundred day moving average price is $332.87.

HCA Healthcare (NYSE:HCA - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $6.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.77 by $0.68. The business had revenue of $18.32 billion for the quarter, compared to analysts' expectations of $18.26 billion. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same period last year, the firm earned $5.36 earnings per share. As a group, research analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 16th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.85%. HCA Healthcare's dividend payout ratio (DPR) is presently 13.11%.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.